University of New Mexico (UNM) Interdisciplinary Substance Use and Brain Injury (ISUBI) Center
Welcome,         Profile    Billing    Logout  
 8 Trials 
27 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kakar, Rishi
uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting
3
240
US
Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support
Usona Institute, Worldwide Clinical Trials
Depressive Disorder, Major
04/25
04/26
NCT06608641: Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Recruiting
3
490
US
Endoxifen enteric-coated tablet (8 mg), Placebo Tablets
Jina Pharmaceuticals Inc., Novum Pharmaceutical Research Services
Bipolar 1 Disorder
06/25
09/25
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder

Completed
2
15
US
ANC-501
Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Major Depressive Disorder
08/23
10/23
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Active, not recruiting
2
350
US
LB-102
LB Pharmaceuticals Inc.
Schizophrenia
12/24
05/25
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
NCT06576843: INDV-6001 Multiple-Dose Pharmacokinetic Study

Recruiting
2
122
US
INDV-6001, Suboxone, Sublocade
Indivior Inc.
Moderate to Severe Opioid Use Disorder
10/25
10/25
NCT06051721: A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants with Generalized Anxiety Disorder (GAD)

Recruiting
2
36
US
CYB004, Psychotherapy
Cybin IRL Limited, Worldwide Clinical Trials
Generalized Anxiety Disorder
11/24
02/25
NCT05321602: Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Completed
1
89
US
LY03010 156 mg treatment group, deltoid, paliperidone palmitate, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal
Luye Pharma Group Ltd.
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
09/22
10/22
NCT03788811: ERG Components in Schizophrenia and Bipolar Disorder Type I

Active, not recruiting
N/A
300
Canada, US, RoW
ERG assessment (RSPA)
diaMentis Inc.
Schizophrenia, Bipolar I Disorder
12/24
12/24
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

Terminated
N/A
138
US
LivaNova
Treatment Resistant Depression
09/24
09/24
Joyce, John
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Active, not recruiting
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
02/25
uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting
3
240
US
Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support
Usona Institute, Worldwide Clinical Trials
Depressive Disorder, Major
04/25
04/26
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension

Enrolling by invitation
3
1400
Europe, Canada, US, RoW
lorundrostat, Placebo
Mineralys Therapeutics Inc.
Hypertension
12/25
12/26
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
REPOSA, NCT06146101: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients with OSA

Recruiting
2/3
560
US
IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo
Incannex Healthcare Ltd
Obstructive Sleep Apnea
12/26
12/26
NCT05583955: A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)

Completed
2
75
US, RoW
NOE-105, Escalating dose levels of NOE-105, Placebo, Placebo to match
Noema Pharma AG
Childhood-Onset Fluency Disorder
10/23
11/23
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Active, not recruiting
2
285
US
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
01/25
02/25
APC-APN-201, NCT06400615: Study That Tests AD109 in Patients Taking GLP-1 Drugs

Active, not recruiting
2
40
US
AD109
Apnimed
OSA
12/24
12/24
NCT06643728: A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Recruiting
2
140
US
Bimagrumab, LY3985863, BYM338, VER201, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
02/26
11/26
Brown, Patricia k
INDV-6000-401, NCT04995029: Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

Completed
4
785
Canada, US
Transmucosal Buprenorphine, Extended-release Buprenorphine, RBP-6000, SUBLOCADE
Indivior Inc.
Moderate to Severe Opioid-use Disorder
06/24
06/24
uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting
3
240
US
Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support
Usona Institute, Worldwide Clinical Trials
Depressive Disorder, Major
04/25
04/26
Panorama, NCT06809595: A Phase 3 Trial of MM120 for Generalized Anxiety Disorder

Recruiting
3
250
US
Placebo, MM120 (LSD D-Tartrate)
Mind Medicine, Inc.
Generalized Anxiety Disorder
11/26
05/27
NCT05407064: A Dose-Finding Study of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

Completed
2
198
US
MM-120 (LSD D-Tartrate), Placebo
Mind Medicine, Inc.
Anxiety Generalized
10/23
11/23
Bobrow, Shelbie
uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting
3
240
US
Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support
Usona Institute, Worldwide Clinical Trials
Depressive Disorder, Major
04/25
04/26
Sotolongo, Louis
uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting
3
240
US
Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support
Usona Institute, Worldwide Clinical Trials
Depressive Disorder, Major
04/25
04/26

Download Options